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Abstract
Purpose. This review summarizes the more prevalent soft tissue tumours arising in the retroperitoneum and highlights
some recent fundamental and diagnostic developments relevant to mesenchymal tumours.
Discussion. The retroperitoneum is an underestimated site for benign and malignant neoplastic disease, and represents the
second most common site of origin of primary malignant soft tissue tumours (sarcomas) after the deep tissues of the lower
extremity. In contrast to the predominance of benign soft tissue lesions over malignant sarcomas elsewhere, retroperitoneal
mesenchymal lesions are far more likely to be malignant. The differential diagnosis is primarily with the more common
lymphoproliferative and parenchymatous epithelial lesions arising in this area, and with metastatic disease from known or
unknown primary sites elsewhere.The most prevalent mesenchymal tumours at this site are of a lipomatous, myogenic or
neural nature.Their generally late clinical presentation and poorly accessible location provides numerous clinical challenges;
optimal radiological imaging and a properly performed biopsy are essential cogs in the management route.Histopathological
diagnosis may be complicated, but has been aided by developments in the ® elds of immunohistochemistry and tumour
(cyto)genetics. Despite signi® cant advances in oncological management protocols, the prognosis remains generally less
favourable than for similar tumours at more accessible sites.
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Introduction
The retroperitoneum represents the lumbo-iliac
anatomical region bounded anteriorly by the
peritoneum, posteriorly by the posterior abdominal
wall, superiorly by the 12th rib and vertebra, inferi-
orly by the sacrum and iliac crest and laterally by the
peripheral margin of the quadratus lumborum
muscles. Present within the retroperitoneum are the
pancreasand duodenum,kidneysand ureters,adrenal
glands,aorta and its branches, inferior vena cava and
its tributaries, lymph nodes and nerve branches, all
embedded in a loose framework of connective tissue.
The relative paucity of vital structures, and the
abundanceof looseconnectivetissuein thisarea,results
in a generally late clinical presentation of space-
occupying lesions. Symptoms tend to be related to
gastrointestinal,urinaryor vascular compromise,when
largelesionalsizeand compression/invasionof adjacent
structuresseverelylimitsthecurativetreatmentoptions.
Collectively,malignant tumours of the retroperito-
neum are roughly four times more frequent than
benign lesions,in sharp contrast to neoplastic disease
occurringelsewhere in the body,where benigndisease
predominates.
1,2
In adults the majority of retroperitonealneoplasms
are primary lymphoproliferative (Hodgkin’s and
non-Hodgkin’s lymphoma) and parenchymatous
epithelial tumours (renal, adrenal, pancreas), or
representmetastatic disease from known or unknown
primary sites elsewhere.
2 In infancy and early child-
hood, nephroblastoma (Wilms’ tumour), neuroblas-
toma and germ cell tumours are the more common
retroperitoneal neoplasms.
3
Softtissue(mesenchymal)tumoursof the retroperi-
toneum are less common; nevertheless 15% of all
primary sarcomas arise within the retroperitoneum,
and consequently this represents the second most
common site for the origin of malignant mesen-
chymal tumours, after the deep tissues of the lower
extremity (thigh).
1 It is the general experience that,
although benign soft tissue lesions at all sites
outnumber their malignant counterparts by a ratio of
at least 100:1, in the retroperitoneum sarcomas are
more prevalent than their benign counterparts. In
comparison with soft tissue lesions elsewhere,
however, the range of commonly encountered retro-
peritoneal mesenchymal neoplasms is more limited,
with the most commonlesions being of a lipomatous,
smooth muscle or neural nature (Table 1).
1,2
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neal lesions generally do not pose signi® cant
diagnostic problems, high-grade sarcomas may
present morphologically as poorly differentiated
tumours lacking distinctive phenotypic features.
Consequently, histomorphological and ultrastruc-
tural analysis may be insufficient for reaching an
accurate (differential) diagnosis in certain cases,
essential for directingpatient management strategies.
Fortunately, it has become apparent over the last
decade that certain soft tissue tumours appear to be
associated with tumour-speci® c genetic alterations
(Table 2), and (cyto)genetic analysis aimed at the
detection of these alterations is a helpful adjunct in
resolving some of these diagnostic dilemmas.
4
Computerized tomography (CT) scanning and
(dynamic) magnetic resonance imaging (MRI) are
the radiological procedures of choice in determining
the extent of local, regional and distant tumour
spread. These procedures are essential for clinical
staging, planning an appropriate and optimal biopsy
procedure prior to de® nitive treatment, as well as
playing an important role in follow-up imaging to
assess efficacy of treatment regimens.
5± 7 Addition-
ally, positron emission tomography (PET) scanning
may,in certain settings,be of clinical use,particularly
in the detection of high-grade sarcomas and the
assessment of local recurrence.
8,9
It is the aim of this short synopsis to discuss the
most prevalent retroperitoneal soft tissue tumours
and associated differentialdiagnoses,and to highlight
some important recent developmentsin fundamental
and diagnostic aspects of mesenchymal tumours.
The histopathology of retroperitonealsoft tissue
tumours
The soft tissues are de® ned as consisting primarily of
extraparenchymatous voluntary muscle, fat, ® brous
(connective) tissue, and the neurovascular supply of
these tissues.
1 Nevertheless, mesenchymal tumours
also regularly arise from the supporting connective
tissues of the various organs and are included in this
review.
Reactive non-neoplastic processes
Retroperitoneal masses may be of a non-neoplastic
or neoplastic nature. Non-neoplastic masses arising
at this site are predominantly of a reactive/
in¯ ammatory or infectious nature, involving either
the organsat this site or the retroperitonealsofttissues.
These generally do not pose a clinical problem,
although periodically the differential diagnosis with
neoplastic disease may be more complicated; for
example the differential diagnosis of reactive ® brosis
Table 1. Soft tissue neoplasms of the retroperitoneum
Malignant Benign
Lipomatous:
Well-differentiated liposarcoma Myolipoma
Dedifferentiated liposarcoma
Myogenic:
Leiomyosarcoma
Neurogenic:
Malignant peripheral nerve sheath tumour (Anciant) schwannoma
Miscellaneous: Neuro® broma
Desmoplastic small round cell tumour
Pleomorphic sarcoma, undifferentiated
Kaposiform haemangioendothelioma
In¯ ammatory myo® broblastic tumour
Table 2. Genetic alterations of diagnostic signi® cance in the sarcoma group
Tumour Genetic alteration Gene(s)
Alveolar rhabdomyosarcoma t(2; 13)(q35;q14) FKHR/PAX3
t(1; 13)(q36;q14) FKHR/PAX7
Atypical lipoma/well-differentiated liposarcoma ring (chr. 12)/marker chromosome ?
Desmoplastic small round cell tumour t(11;22)(p13;q12) EWS/WT1
Ewing’s sarcoma/PNET t(11;22)(q24;q12) EWS/FLI1
t(21;22)(q22;q12) EWS/ERG
t(7; 22)(p22;q12) EWS/ETV1
Gastrointestinal stromal tumour mutation chromosome 4q11-21 c-kit
losses chromosome 14q
Myxoid liposarcoma t(12;16)(q13;p11) CHOP/FUS
t(12;22)(q13;q11) CHOP/EWS
Synovial sarcoma t(X; 18)(p11.2;q11.2) SYT/SSX1
SYT/SSX2
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10/
idiopathic retroperitoneal ® brosis (an in¯ ammatory/
reactive process often presenting as a mass)
11,12/
retroperitoneal ® bromatosis,
12 at this site regularly
seen in the context of Gardner’s syndrome
13/
® brosarcoma (rare),
12 and the differential diagnosis
of xanthogranulomatous pyelonephritis
(in¯ ammatory)
14/(sarcomatoid) renal cell
carcinoma
15/soft tissue sarcoma with a xanthogranu-
lomatous morphology.
12
Neoplastic disease
As alluded to earlier, the majority of retroperitoneal
tumours are primary lymphoproliferative and paren-
chymatous epithelial tumours.
The majority of lymphomas are non-Hodgkin’s
B-cell type, but these may be associated with a vari-
able degreeof contiguous® brosis/sclerosissometimes
complicating the clinical differential diagnosis as
mentioned above.
2,10
Epithelial tumours arising in the kidneys, ureters,
adrenals and pancreas may invade the retroperito-
neal soft tissues. Although the various tumour
subtypes may pose diagnostic problems, these
tumours are histopathologically rarely difficult to
distinguish from non-epithelial lesions, particularly
with the use of immunohistochemistry.
Primary retroperitoneal seminomatous and
non-seminomatous extra-gonadal germ cell tumours
are less frequent, although teratomas occur in a
relatively greater percentage of children.
16,17
Additionally embryological remnants such as tailgut
cysts and other anomalies may occur in the
retroperitoneal/sacral area, rarely undergoing
malignant change.
18
Metastatic disease to the retroperitoneum, from a
gamut of intra- and extraperitoneal sites, represents
another signi® cant proportion of mass lesions at this
site and needs to be considered in any differential
diagnosis. Metastases from an undifferentiated
carcinoma may create difficulties in the differential
diagnosis with primary spindle cell tumours of the
retroperitoneum, although this dilemma is usually
resolved with an appropriate immunohistochemical
panel including cytokeratins.
The majority of soft tissue tumours arising in the
retroperitoneum (Table 1) are of a lipomatous,
myogenic or neurogenic nature and are discussed
below.
1. Lipomatous tumours. LipomaÐ Myolipoma (lipo-
leiomyoma), a benign encapsulated lesion of variable
size and composed of an admixture of mature
adipocytes and bundles of smooth muscle may be
encountered in the retroperitoneum.
19 Nevertheless,
pureretroperitoneallipomas are a poorly documented
and contentious entity
20± 22 and, although they
theoretically must occur, all lipomatous tumours at
this site should probably be regarded with a high
level of suspicion for malignancy.
LiposarcomaÐ Liposarcomasare the mostcommon
soft tissue tumours occurring within the retroperito-
neum,and probablyaccountfor 25± 35% of all mesen-
chymal lesions at this site.
21± 23 Although the
liposarcoma group is subdivided into well-
differentiated liposarcoma, dedifferentiated liposar-
coma, myxoid/round cell liposarcoma, and
pleomorphic liposarcoma, the majority of retroperi-
toneal liposarcomas are of the well-differentiated and
dedifferentiated type.
22 Myxoid/round cell liposar-
coma occur far less frequently in the retroperito-
neum, while pleomorphic liposarcoma at this site is
very rare.
22 Well-differentiated and dedifferentiated
liposarcoma should probably be regarded as related
entities since the latter often arises from/within the
former,
23± 25 and common genetic alterations are
present in these tumours (ring chromosomesderived
from chromosome12 and largemarkerchromosomes;
Table 2).
26,27 Similarly (cyto)genetic analysis has
established that the vast majority (75%) of myxoid
and round cell liposarcomas share a common t(12;
16)(q13; p11) translocation (Table 2), indicating that
these tumours probably represent the low-grade and
high-grade components respectively of a single
tumour entity.
4,22,27 Furthermore, myxoid liposar-
coma has also been reported to undergo dedifferen-
tiation, suggesting a closer relationship between
myxoid and well-differentiated liposarcoma than
previously thought.
28
Clinically,distinctionbetween the various categories
within the liposarcoma group remains important due
to their different modes of biological behaviour.
22,29
Liposarcomas may be of variable size (reaching
sizes of more than 20 cm), are often well-
circumscribed/encapsulated, and frequently show a
distinct lobulation. The cut surface has a variable
morphology dependent on tumour type.
(A) Well-differentiated and dedifferentiated liposar-
coma. Well-differentiated liposarcoma is composed
of a background of mature-looking adipocytes
(although nuclei tend to be slightly larger and more
pleomorphic), with a variable scattering of lipoblasts
each containinga singleatypical,hyperchromatic,scal-
loped (indented), and eccentrically located nucleus
with one or more scattered cytoplasmic lipiddroplets/
vacuoles. The tumour may be traversed by dense
bands of variably cellular collagen and demonstrate a
variable in¯ ammatory cell in® ltrate composed of
lymphocytes and plasma cells;histopathologically the
diagnosis is rarely troublesome.
Although well-differentiated liposarcomas have
been subtyped (lipoma-like, in¯ ammatory, sclerosing
variants) dependent on the degree of ® brosis and
in¯ ammatory in® ltrate, the clinicopathological
relevance of this is debatable since combinations of
the various morphologies may be seen in individual
tumours.
22,30
Dedifferentiated liposarcoma generally consists of
well-differentiated areas with a sharp transition to
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demonstratingeither a low-grade® bromatosisor well-
differentiated ® brosarcoma morphology, or a high-
grade ® brosarcoma or undifferentiated sarcomatous
morphology; occasionally the dedifferentiated areas
may resemblecarcinomaor melanoma.
31Dedifferen-
tiation to more than one histogenetic tissue type (for
example osteo- or chondrosarcoma) may occur in a
minorityof cases.
31The differentialdiagnosisof dedif-
ferentiated liposarcoma with other low- or high-
grade retroperitoneal spindle cell lesions is often
difficult and may require extensive sampling of the
de® nitive surgical specimen to identify the lipoma-
tous component.
Well-differentiated liposarcoma is regarded as a
low-gradesarcomathat doesnotmetastasize.
23,24,32,33
However, recurrence rates are high (approaching
100% in the retroperitoneum due to the generally
late presentationÐ and consequently large sizeÐ and
problematic surgery) and a signi® cant proportion
(10± 20%) will dedifferentiate over a mean period of
7± 8 years with an acquisitionof the capacity to metas-
tasize, irrespective of the extent of dedifferentia-
tion.
32 Following treatment for dedifferentiated
liposarcoma, the reported rates of local recurrence
and metastatic disease are variable; local recurrence
occurring in 40± 100% of cases and distant metas-
tases in roughly 20% of cases.
31,34 However, the
general impression remains that these tumours prob-
ably exhibit a less aggressive behaviour than dediffer-
entiated sarcomas in general.
31
(B) Myxoid/round cell liposarcoma. Myxoid liposar-
coma, far less common in the retroperitoneum,
consists of an abundant hyaluronidase-sensitive
myxoid matrix with small bland spindle-shaped or
more rounded cells, univacuolated (signet ring-like)
lipoblasts, and sporadic multivacuolated lipoblast-
s.The vasculature is composed of a delicate plexi-
form arrangementof thin-walled capillaries described
as having a chicken wire or crow’s feet distribution.
The presence of a more cellular (round cell)
component is associated with a more aggressive
biological behaviour.
33,35,36 Since no histopatho-
logical consensushas been reached on the percentage
of the round cell component required for an
unambiguous diagnosis of high-grade round cell
liposarcoma, we tend to report these neoplasms as
mixed myxoid and round cell liposarcoma and give
an approximation of the percentage round cell
component present.
Depending on the extent of a round cell
component,the differentialdiagnosisis primarily with
malignantperipheralnerve sheath tumour (MPNST)
and desmoplastic small round cell tumour
(DSRCT).
37 This distinction is generally based on
the relationship of the tumour to a large nerve trunk
on imaging (MPNST),lack of coexpressionof neural
epithelial and mesenchymal markers (DSRCT), the
degree of S100 protein positivity (spotty in MPNST,
variably diffuse in liposarcoma), as well as cytomor-
phology.The presence of the characteristic t(12; 16),
and lack of the t(11; 22)(p13; q12) translocation
found in DSRCT (Table 2),
4 is a powerful adjunct.
Puremyxoidliposarcomais regardedas a low-grade
sarcoma. A metastatic potential exists, however, in
about 10± 20% of cases, although this correlation
probably depends on the adequacy of tumour
sampling (inadequate sampling will fail to identify a
round cell component).
33,36 Furthermore, while a
myxoid liposarcoma with a round cell component of
more than 5± 10% is regarded as having a signi® cant
metastatic risk, caution is necessary since no clear
criteria are present for tumour grading,and there are
often problems with tumour sampling.
35,36
2. Myogenic tumours. LeiomyomaÐ Primary leio-
myoma of the retroperitoneum is an extremely rare
occurrence and should be diagnosed with extreme
caution (see below).
2
LeiomyosarcomaÐ Leiomyosarcomas of the retro-
peritoneum are the second most common primary
malignant sarcoma at this site, after liposarcomas.
1
This tumourshould notbe groupedwith the gastroin-
testinal stromal tumours (GIST) of the small and
large intestine (occasionally seen in the retroperito-
neum as a result of local spread), a complex group of
tumours postulated to arise from pacemaker cells
(interstitial cells of Cajal) located in the wall of the
bowel, and demonstrating a variety of differentiation
patterns (see below).
38,39
Roughly two-thirds of leiomyosarcomas occur in
women with an average age at presentation of 60
years.The tumours are of variable size (average size
10± 20 cm), and at surgery often involve adjacent
structures by direct spread.Tumours often show foci
of haemorrhage,necrosis and cystic change.
40 Histo-
logically,the general architecture is that of a fasicular
tumour. Cell morphology can be highly variable,
ranging from well-differentiated to anaplastic, but
the typical cell is elongated and tapering, contains a
cigar-shaped nucleus with obvious pleomorphism,
bipolar perinuclearglycogen-containingvacuoles and
eosinophiliccytoplasm.The detectable mitotic activity
may be highly variable and, since it is the general
experiencethat even tumourswith 1± 4 mitoses/2 mm
2
can metastasize, all tumours with obvious nuclear
atypia (irrespective of the mitotic activity) should be
regarded as potentially malignant when occurring in
the retroperitoneum.
1 Immunohistochemically there
is variable expressionof muscle-speci® c actin (MSA),
smooth muscle actin (SMA) and desmin; S100
protein and CD34 expression are absent.Although a
partial deletion of chromosome1p is presentin about
50% of cases, no tumour-speci® c genetic alterations
are consistentlypresent,sincethis deletion also occurs
in other soft tissue tumours.
41
The differential diagnosis is primarily with spindle
cell MPNST and ® brosarcoma, generally resolvable
20 J. Frans GraadtVan Roggen & Pancras C.W . Hogendoornusingimmunohistochemistry(desmin positive,S100-
protein negative).
These tumours are highly aggressive with a 5-year
survival between 0 and 20%.
40
RhabdomyosarcomaÐ Rhabdomyosarcoma,
although infrequently seen in the retroperitoneum,
needsto be considered.
42,43This is primarilya tumour
of children and young adults and, of the three
describedsubtypes (embryonal,alveolar and pleomor-
phic rhabdomyosarcoma), embryonal rhabdomyosa-
rcoma is the most common retroperitoneal tumour,
while the alveolar and pleomorphic subtypes are
extremely unusual at this site. The presence of the
characteristic t(2;13)(q35;q14)/t(1;13)(p36;q14)
translocations present in the vast majority of alveolar
rhabdomyosarcoma may be of diagnostic use
44± 46
(Table 2).
3.Neurogenic tumours.SchwannomaÐ Schwannoma,
includingthe cellular variant (cellular schwannoma),
is the most common neurogenic soft tissue tumour
occurring in the retroperitoneum.
47
Clinically, these lesions have a broad age range of
presentation, and often occur paravertebrally.
Macroscopically, both schwannoma and cellular
schwannoma are encapsulated nodular tumours,
regularlyseen in association with a nervetrunk,which
may be extremelylargeat presentation.On sectioning,
the classical schwannoma has a variably tan, haemor-
rhagicand cystic appearance,while the cellularvariant
is ® rmer and more homogeneouslytan in colour.
Microscopically, the schwannoma is characterized
by the classical Antoni A areas composed of fasicles
of spindle-shaped cells with focal nuclear palisading,
hypocellular and mucoid Antoni B areas, Verocay
bodies, and vascular hyalinization. The cellular
schwannoma, however, as its name suggests,is more
cellular, composed primarily of Antoni A areas and
frequently has capsular and perivascular lymphocytic
aggregates.Whileobvious nuclear pleomorphism and
mitotic activity is generally absent in the classical
schwannoma,mild nuclear pleomorphismand a vari-
ably lowmitotic activity (notmorethan fourmitoses/2
mm
2) may be seen in the cellular schwannoma
complicatingdiagnosis,particularly when the patholo-
gist receives a minute needle-core biopsy.
48,49 An
accurate diagnosisis of signi® cantclinicalimportance
since the risks of complicated surgery at this site for
what is a benign lesionshouldbe properlyconsidered.
The differentialdiagnosisis with MPNST and other
spindlecell tumours,although the strong diffuse posi-
tivity for S100-protein, (peri)vascular hyalinization
and AntoniA areas should in most cases facilitate the
correct diagnosis.
Both tumoursare benign and although local recur-
rences have been noted for cellular schwannoma, no
metastases have been documented.
50
Neuro® bromaÐ Neuro® bromas, identical to their
counterparts elsewhere, are also periodically
encountered in the retroperitoneum.
Malignant peripheral nerve sheath tumourÐ
MPNSTs are de® ned as malignant mesenchymal
tumoursarising from,or differentiating towards,cells
of the peripheral nerve sheath, but excludingepineu-
rial tumours and tumours arising from the neural
vasculature.
51Roughlytwo-thirds of cases are associ-
ated with a preexisting neuro® broma, while
approximately half of MPNSTs arise in patients with
neuro® bromatosisI (NF I)(presumablyhaving arisen
within a neuro® broma).
52 MPNSTs are tumours of
adults, although the age at presentation in patients
with NF I is younger than in unaffected patients.
52
Macroscopically,tumoursare nodularand ® rm and
may show extensive necrosis. Microscopically, these
tumour have a highly varied morphology (well-
differentiated to anaplastic),although the prototypical
lesion is cellular with a fascicular architecture; cells
are elongated and tapering with wavy, pleomorphic
and hyperchromatic spindled nuclei. Mitoses are
frequent ( 4/2 mm
2). Classically S100-protein
staining is focal and weak to variably prominant.The
presence of a rhabdomyoblastic component
(malignant Triton tumour), con® rmed by positive
myogenicimmunohistochemistry,is an extremelyrare
® nding and may occur both within and outside the
setting of NF I.
53
MPNST is a high-grade tumour with an extremely
poor prognosis ( 20± 30% 5-year survival).
52
4. Pleomorphic sarcomas. So-called `malignant ® brous
histiocytoma’ (MFH) is frequently regarded, prob-
ably incorrectly, as a speci® c diagnostic entity and
used to denote a group of tumourswith an anaplastic
morphology and without detectable evidence of soft
tissue differentiation using current immunohisto-
chemical methods. Although this remains a
controversial area, it is now likely that these tumours
represent a heterogeneousgroup of extremely poorly
differentiated tumours which are as yet not histoge-
netically classi® able with current techniques.
54 It is
our preference to report these tumours as high-grade
pleomorphicsarcomas without detectable differentia-
tion (NOS),and to avoid the non-speci® c label MFH.
5. Miscellaneous retroperitoneal soft tissue tumours. In
addition to the above-mentioned tumours, a variety
of less common mesenchymal tumours are
encountered in the retroperitoneum.
Desmoplastic small round cell tumour
(DSRCT)Ð DSRCT, a malignant tumour of
children,adolescentsand young adults and belonging
to the morphological category of small blue round
cell tumours (including Ewing’s sarcoma, embryonal
rhabdomyosarcoma, lymphoma), periodically occurs
at this site.
55 Histologically the tumour is composed
of solid nests of small round to polygonal cells set
within a dense desmoplastic stroma. Important
diagnostic features are the coexpression of epithelial,
neural and mesenchymal markers, and the frequent
presence of a tumour-speci® c t(11;22)(p13;q12)
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some 22, and the WT1 (Wilms’tumour 1) gene on
chromosome 1 (Table 2).
56
Gastrointestinal stromal tumours (GIST)Ð The
GIST category represents a set of mesenchymal
tumours most commonly present in the stomach and
small intestine of adults, periodically involving the
retroperitoneum either by direct extension from the
intra-abdominal gastrointestinal tract, or origin in
the retroperitoneal portion of the duodenum.
39This
complex group of tumours are important in the
differential diagnosis since they are immunohisto-
chemically and genetically distinct from the classical
leiomyoma/leiomyosarcoma, and are postulated to
arise from intramural `pacemaker cells’ (interstitial
cells of Cajal), demonstrating myomatous and/or
neural differentiation.
39,57
These spindle and/or epithelioid tumours gener-
ally express CD117, in contrast to smooth muscle
tumours. A spectrum of biological behaviour is
present, as yet difficult to predict on histomorpho-
logical basis (although a large size and a mitotic
activity >5/2 mm
2 are pointers of aggression).
38 A
proposed association with cellular Epstein± Barr virus
infection has never been convincingly supported.
57
At the genetic level a proportion of these tumoursare
characterized by mutations in c-kit proto-oncogene
(CD117) on chromosome 4q11-21, coding for a cell
surface receptor with a tyrosine kinase function, and
although this is not entirely tumour-speci® c it is
extremely helpful in the differential diagnosis with
other retroperitoneal spindle cell lesions.
39,58
Kaposiform hemangioendotheliomaÐ This is an
uncommon vascular tumour occurring primarily in
young children, with the retroperitoneum being one
of the preferential sites of origin.
59 Macroscopically
the tumour is poorly circumscribedwith a grey/white
appearance.Microscopicallyirregularcellular lobules
with in® ltrative margins are seen consisting of a
mixture of capillariform vessels often containing
microthrombi, slit-like endothelial-lined vascular
spaces and spindly endothelial cells. Haemosideren
deposition is variably present. Nuclear pleomor-
phism is mild and mitoses scarce. The differential
diagnosis is with Kaposi sarcoma, a tumour rarely
found in childhood, lacking a lobular architecture
and containing a variable in¯ ammatory in® ltrate.
Clinically the lesion does not appear to metastasize,
and it is the locally invasive natureof the lesion which
is responsible for the high mortality rate.
Solitary ® brous tumour (SFT)Ð SFT, a lesion of
adults which can be either benign or malignant and
originally described as a pleural lesion,has now been
described at numerous sites including the retroperi-
toneum and pancreas.
60,61Although the morphology
may be highly variable, the classical examples have a
`hemangiopericytoma-like’vascular pattern and
fascicles of CD34 positive spindle shaped cells
intermingled with collagen bundles.The presence of
signi® cant atypia, necrosis and more than four
mitoses/2 mm
2 are poor prognostic factors although
reliable prediction of their biological behaviour is
impossible. In the differential diagnosis with other
spindle cell tumours, the CD34 positivity is very
useful.
HaemangiopericytomaÐ Haemangiopericytoma,
as a distinct clinicopathological neoplasm, remains a
contentious entity and various schools of thought
exist concerning this subject
62,63 Since a number of
different tumours may exhibit the presumed typical
`haemangiopericytoma-like’ morphology in the
absence of the expected typical myoid immunohisto-
chemical phenotype, it is probable that this may not
represent a single entity but rather represent a variety
of differenttumourssharinga `haemangiopericytoma-
like’ morphology. Nevertheless, not all tumours with
a `haemangiopericytoma-like’ morphology can be
readily categorized as alluded to,leaving a smallsubset
of lesionswhose true natureremains contentious.
62,63
Paraganglioma(includinga pigmentedvariant),
64,65
® bromatosis,
66 in¯ ammatory myo® broblastic
tumour,
67 synovial sarcoma,
68 vascular intimal
sarcoma,
69 malignant mesenchymoma,
70 rhabdoid
tumours,
71 extraskeletal Ewing’s sarcoma
72 and
extraskeletal osteosarcoma,
73,74 all described at this
site, are infrequently encountered but nevertheless
may enter the differential diagnosisof retroperitoneal
soft tissue tumours.
Role of ® ne needle aspiration/needle core biopsy
Depending on the site of the retroperitoneal lesion,
® ne needle aspiration/needle core biopsy may or may
not be practically tenable. Fine needle aspiration
(FNA), when possible, may be very useful as a ® rst
step in resolving the differential diagnosis of primary
or metastatic carcinoma, a lymphoproliferative
disorder,or a mesenchymal tumour.Once carcinoma
and lymphoma have been excluded, its usefulness is
limited since attempts at classi® cation of mesen-
chymal tumours on FNA material, except in expert
hands,
75 is probably unreliable and not advisable.
The role of a needle core biopsy is probably
controversial. While most retroperitoneal soft tissue
lesions are probably malignant (except schwan-
noma), and will need some form of de® nitive opera-
tive procedure (including schwannomas as a result of
a local mass effect), the risk of tumour spill following
a needle core biopsy needs to be weighed up against
the possibility/need for an optimal surgical interven-
tion.
Tumour grading, reporting and clinical staging
Tumour grading, originally developed for soft tissue
tumours located within the extremeties, represents a
histological assessmentbased primarily on the degree
22 J. Frans GraadtVan Roggen & Pancras C.W . Hogendoornof tumour differentiation, mitotic activity and the
extent of tumour necrosis.
76,77 In the absence of
sufficient data concerning the clinical course of
speci® c tumour types, due to their relative rarity, the
intention was to try and provide an indication of the
potential degree of malignancy of a lesion in order to
be able to separate lesions with a good prognosis
from lesions with a poor prognosis and hence to
facilitate decisionswith respect to the choice of treat-
ment modalities available.
76,77
Histological type, however, increasingly appears to
be the most important parameter in determining
clinical behaviour; for example synovial sarcoma is
by de® nition a high-grade tumour irrespective of
mitotic activity and extent of necrosis while in
extraskeletal myxoidchondrosarcoma,patient age and
tumour size appear to be the most important
prognostic factors.
78 Consequently, while grading
systems may broadly speaking be of clinical value, it
is envisaged that increasingly tumour-speci® c factors
will be identi® ed having an important bearing on
individual tumour behaviour.
Clinical staging of musculoskeletal tumours, via
clinical examination, radiological imaging (local
spread, presence of metastatic disease) and
histopathological examination, serves to document
the nature and extent of the disease, ideally at the
time appropriate treatment is being initiated, and
aimsto guidetherapy and provideprognosticinforma-
tion. While initiated by Enneking (Musculoskeletal
Tumor Society staging system;
79,80Table 3), a second
(modi® ed) staging system, designed by the American
Joint Committee on Cancer (AJC) and based on the
TNM system (tumour size; involvement of lymph
nodes; presence of metastases) and incorporating
histological tumour grade, is also in use
81 (Table 4).
While the Enneking system (with its emphasis on
compartmentalization) is best suited for sarcomas
arising in the extremeties, the AJC system can be
used for tumours at any site but is somewhat more
complex.
Recently, the AmericanAssociation of Directors of
Anatomic and Surgical Pathology have provided
recommendations for reporting common malignant
tumours including soft tissue sarcomas.
82Their aim
was to provide a framework for an informative and
clinicallyusefulreportto facilitate the efforts at staging
and choice of optimal therapeutic regimens.
Table 3.The MusculoskeletalTumor Society staging system
Stage* Grade² Site‡ Metastases
Benign 1 G0 T0 no
2 G0 T1 no
3 G0 T1/2 no/yes
Malignant IA G1 T1 no
IB G1 T2 no
IIA G2 T1 no
IIB G2 T2 no
IIIA/B G1/2 T1/2 yes
A frequently used staging system for benign and malignant musculoskeletal tumours of the
extremeties.This system is not particularly applicable to retroperitoneal tumours where the
concept of compartmentalization is a moot point.
*Stage:A=intracompartmental; B=extracompartmental.
² Grade: G0=benign; G1=low-grade malignant; G2=high-grade malignant.
‡ Site:T0=intracapsular;T1=extracapsular,intracompartmental;T2=extracapsular,extracom-
partmental.
Table 4. American Joint Committee on Cancer staging system
Stage Grade* Tumour² Lymph nodes‡ Distant metastases§
Ia G1 T1 N0 M0
Ib G1 T2 N0 M0
IIa G2 T1 N0 M0
IIb G2 T2 N0 M0
IIIa G3/4 T1 N0 M0
IIIb G3/4 T2 N0 M0
IVa G1± 4 T1/2 N1 M0
IVb G1± 4 T1/2 N0± 1 M1
A widely used staging system for malignant musculoskeletal tumours, and applicable to soft
tissue tumours in the retroperitoneum.
*Histological grade: G1=low (well-differentiated); G2=moderate (moderately well-
differentiated); G3=high (poorly differentiated);G4=undifferentiated.
² Tumour size:T1=less than 5 cm in diameter;T2=5 cm or more in diameter.
‡ Lymph node status: N0=no lymph node metastases; N1=lymph node metastases.
§Distant metastases: M0=absent; M1=present.
Soft tissue tumours of the retroperitoneum 23Conclusion
This brief review has highlighted the most common
soft tissue tumours presenting in the retroperito-
neum. Recent developments, particularly in the area
of tumour genetics, are becoming increasingly useful
in the diagnostic arena, and are gradually improving
ourknowledgeabouttumourhistogenesisand biology.
It is envisaged that a greater mechanistic
understanding of tumour biology and improved
diagnostic accuracy will provide optimal and tumour-
speci® c therapeutic regimens.
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